Go to Top


Calvert Research And Oncoceutics Announce Investment Partnership To Advance ONC201 To An IND Filing

CARY, NC and HUMMELSTOWN, PA (October 1, 2013). Calvert Research, LLC, a business unit of Calvert Holdings, Inc., and Oncoceutics, Inc. announced the execution of an Investment Partnership Agreement to support completion of preclinical studies for ONC201, Oncoceutics’ experimental anti-cancer compound. Under the terms of the Agreement, Calvert Research will utilize the extensive resources of its CRO affiliate, Calvert Laboratories, Inc., to complete animal pharmacology, toxicology, and pharmacokinetic testing and conduct bioanalytical studies on ONC201 to support the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by the end of 2013. In conjunction with performing these studies, Calvert Research has made a significant investment

Read More

Calvert Research Awarded Federal Grants to Support Further Development of Its Drug Candidate

Cary, NC–Calvert Research, LLC announced today that one of the Company’s therapeutic development programs (T1-1081) qualified to receive federal grant funding totaling approximately $245,000 under the Patient Protection and Affordable Care Act of 2010 (“The ACT”), which will be used to help advance T1-1081 toward an IND application filing. The Act created a $1.0 billion federal program to provide grants or tax credits to help support certain “Qualifying Therapeutic Discovery Projects” that have been designated by the Department of Health and Human Services using the following criteria: (a) the potential to create a novel therapy to treat unmet medical needs; (b) the potential to reduce long-term health care costs in

Read More

Calvert Holdings Announces Executive Changes for Calvert Research

April 8, 2010: Calvert Holdings, Inc. announced today a restructuring of executive responsibilities within in its Calvert Research, LLC business unit, effective April 1st, 2010. Michael A. Recny, Ph.D. has been appointed as President of Calvert Research, LLC, assuming the position currently held by Russ McLauchlan, Chairman & Chief Executive Officer of Calvert Holdings, Inc. “Michael and I have now worked together for several years, and I have come to appreciate that he is a highly competent individual who has a keen ability to balance his skills as an experienced scientist and successful drug developer with appropriate business insight and discipline” said Russ McLauchlan.  “Together we formed Calvert BioCapital, a new venture

Read More